Molsidomine Arrow

Molsidomine, the active ingredient in Molsidomine Arrow, is a nitric‑oxide (NO) donor presented as an oral tablet for oral administration. It belongs to the anti‑anginal therapeutic class and is indicated for the management of stable angina pectoris in adult patients, helping to reduce myocardial oxygen demand. The drug is marketed within the European Union and requires a prescription.

GNH USA supplies Molsidomine Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory compliance.

Molsidomine is used in the anti‑anginal drug class to improve myocardial oxygen balance in patients with chronic coronary disease. - Stable angina pectoris: reduces frequency of chest pain episodes and improves exercise tolerance. - Chronic stable angina: decreases myocardial oxygen demand during physical activity. - Ischemic heart disease: helps prevent anginal attacks by promoting vasodilation.

Molsidomine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warm sensation and redness of the skin. - Dizziness or light‑headedness, especially on standing. - Nausea or mild gastrointestinal discomfort. - Hypotension: modest reduction in blood pressure. - Tachycardia: compensatory increase in heart rate.

Serious or Rare Side Effects: - Severe hypotension leading to syncope. - Allergic reactions such as rash, pruritus, or angioedema. - Rare cases of Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hemolytic anemia in susceptible individuals. - Hepatic dysfunction manifested by elevated transaminases. - Life‑threatening arrhythmias in patients with pre‑existing conduction disorders.

Before prescribing Molsidomine, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Renal impairment: dose adjustment may be required. - Hepatic impairment: use with caution and monitor liver function. - Concomitant nitrates: avoid due to additive hypotensive effect. - Elderly patients: monitor blood pressure closely for orthostatic changes. - Pregnancy and breastfeeding: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Molsidomine can interact with several cardiovascular agents, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): additive vasodilatory effect may cause severe hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of profound blood pressure drop.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (ACE inhibitors, ARBs, calcium channel blockers): may enhance blood‑pressure‑lowering effect. - Beta‑blockers: possible additive effect on heart‑rate reduction. - Diuretics: may increase orthostatic hypotension risk.